FDA
-
-
-
-
-
-
-
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Ob
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
-
-
-
-
-
-
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demon
-
-
-
-
-
323,324 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

